Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.
Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the company announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.
Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.
In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.
Poseida Therapeutics announces dosing of first patient in phase 1 clinical trial of P-PSMA-101 autologous CAR-T for metastatic castration-resistant prostate cancer.
Poseida Therapeutics raises a $30,500,000 series B round from Tavistock Group, Longitude Capital, Vivo Capital and Malin Corporation.
VP, Regulatory Affairs
Devon J. Shedlock
VP, Preclinical Development
VP, Business Development
VP, Clinical Development Operations and Project Management
VP, Quality Operations
VP, Corporate Affairs
Mark J. Gergen
Chief Business Officer and Chief Financial Officer
VP, Technical Operations
Matthew A. Spear
Chief Medical Officer
Paiman Peter Ghoroghchian
Chief Technical Officer
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
Poseida Therapeutics, Inc.
Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments